Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trevi TherapeuticsTRVI -3.08%22 Market Cap is $2,553.17 Mil as of Aug. 10, 2026. GuruFocus rates TRVI with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,419 Biotechnology companies, Trevi Therapeutics ranks better than 90.27% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Trevi Therapeutics's share price for the quarter that ended in Jun. 2026 was $18.65. Trevi Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 156.60 Mil. Therefore, Trevi Therapeutics's market cap for the quarter that ended in Jun. 2026 was $2,920.63 Mil.
Trevi Therapeutics's quarterly market cap
declined
from Dec. 2025 ($1,606.39 Mil) to Mar. 2026 ($1,531.94 Mil) but then
increased
from Mar. 2026 ($1,531.94 Mil) to Jun. 2026 ($2,920.63 Mil).
Trevi Therapeutics's annual market cap
increased
from Dec. 2023 ($91.50 Mil) to Dec. 2024 ($385.64 Mil) and
increased
from Dec. 2024 ($385.64 Mil) to Dec. 2025 ($1,606.39 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Trevi Therapeutics's Enterprise Value for Today is $2,234.91 Mil.
Trevi Therapeutics (NAS:TRVI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Trevi Therapeutics Market Cap Related Terms
Trevi Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Trevi Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Trevi Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trevi Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Trevi Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Trevi Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Trevi Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trevi Therapeutics (TRVI) has a Market Cap of $2,553.17 Mil as of Aug. 10, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Trevi Therapeutics and its competitors. According to the industry distribution chart, Trevi Therapeutics ranks #138 out of 1419 companies in the Biotechnology industry, placing it in the top 9.7%.
Is Trevi Therapeutics' Market Cap too high?
Trevi Therapeutics' current Market Cap is $2,553.17 Mil. The Biotechnology industry median Market Cap is 116.54. Trevi Therapeutics' value of $2,553.17 Mil is 2090.9% above this industry median. Based on the distribution chart, Trevi Therapeutics ranks #138 out of 1419 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Trevi Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Trevi Therapeutics' Market Cap compare to IMNM and VERA?
According to the Biotechnology industry distribution chart, Trevi Therapeutics ranks #138 out of 1419 companies for Market Cap. This places Trevi Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Market Cap is 116.54. Trevi Therapeutics' value of $2,553.17 Mil is 2090.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.54, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trevi Therapeutics's current Market Cap of $2,553.17 Mil is 2090.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Trevi Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 116.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trevi Therapeutics's current Market Cap is $2,553.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trevi Therapeutics stock overvalued right now?
Trevi Therapeutics (TRVI) has a current Market Cap of $2,553.17 Mil. The current Market Cap is $2,553.17 Mil and 2090.9% above the Biotechnology industry median of 116.54. Trevi Therapeutics' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Trevi Therapeutics (TRVI), the current Market Cap is $2,553.17 Mil as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
22GF Score
Get the complete analysis for TRVI
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRVI has been successfully added to your 
